公开(公告)号：US20220257783A1

公开(公告)日：2022-08-18

申请号：US17688707

申请日：2022-03-07

Applicant: BioNTech SE

Inventor： Ozlem Tureci ,  Ugur Sahin ,  Sebastian Kreiter

IPC: A61K47/64 ,  C07K14/47 ,  C07K14/74 ,  A61K48/00

Abstract: The present invention relates to fusion molecules of antigens, the nucleic acids coding therefor and the use of such fusion molecules and nucleic acids. In particular, said invention relates to fusion molecules, comprising an antigen and the trans-membrane region and cytoplasmic region of a MHC molecule and/or the cytoplasmic region of a MHC or a SNARE molecule.

公开(公告)号：US20220249704A1

公开(公告)日：2022-08-11

申请号：US17565842

申请日：2021-12-30

Applicant: BioNTech SE

Inventor： Ugur Sahin ,  Alptekin Güler ,  Andreas Kuhn ,  Alexander Muik ,  Annette Vogel ,  Kerstin Walzer ,  Sonja Witzel ,  Stephanie Hein ,  Özlem Türeci ,  Gábor Boros ,  Azita Josefine Mahiny ,  Jonas Reinholz ,  Katalin Karikó

IPC: A61K48/00 ,  A61P35/00 ,  A61K39/00 ,  A61K31/7088 ,  A61K39/12

Abstract: Disclosed herein are RNA polynucleotides comprising a 5′ Cap, a 5′ UTR comprising a cap proximal sequence disclosed herein, and a sequence encoding a payload. Also disclosed herein are compositions and medical preparations comprising the same, and methods of making and using the same.

公开(公告)号：US20220093209A1

公开(公告)日：2022-03-24

申请号：US17539157

申请日：2021-11-30

Applicant: BioNTech SE ,  TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gG

Inventor： Ugur Sahin ,  Arbel David Tadmor ,  John Christopher Castle ,  Sebastian Boegel ,  Martin Löwer

IPC: G16B20/20 ,  G16B20/00 ,  A61K39/00 ,  C12Q1/6886

Abstract: The present invention relates to methods for predicting T cell epitopes. In particular, the present invention relates to methods for predicting whether modifications in peptides or polypeptides such as tumor-associated neoantigens are immunogenic or not. The methods of the invention are useful, in particular, for the provision of vaccines which are specific for a patient's tumor and thus, in the context of personalized cancer vaccines.

公开(公告)号：US11046745B2

公开(公告)日：2021-06-29

申请号：US15741902

申请日：2015-07-14

Applicant: BioNTech SE ,  TRON—Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg-Universitat Mainz gGmbH ,  JPT Peptides Technologies GmbH

Inventor： Ugur Sahin ,  Laura Marie Kring ,  Markus Fiedler ,  Matin Daneschdar ,  Hans-Ulrich Schmoldt ,  Ulf Reimer ,  Karsten Schnatbaum

IPC: A61K38/08 ,  C07K7/06 ,  G01N33/566 ,  G01N33/68 ,  C07K14/725 ,  A61K47/64 ,  A61K47/66 ,  C12N15/62 ,  A61K38/00

Abstract: The present invention provides molecules that mimic antigenic determinants of the CD3 (cluster of differentiation 3) T-cell co-receptor epsilon chain (CD3ε). These molecules compete with CD3ε for binding to a CD3ε binding domain. e.g. a CD3ε binding domain of an antibody, and are capable of detecting antibodies against CD3ε. The mimotopes of the invention may be used to generate or inhibit immune responses in animals and preferably humans. Additionally, they may serve as tools for anti-CD3ε antibody purification and the detection of anti-CD3ε antibodies in biological samples.

公开(公告)号：US10968280B2

公开(公告)日：2021-04-06

申请号：US16779011

申请日：2020-01-31

Applicant: GENMAB A/S ,  BIONTECH SE

Inventor： Isil Altintas ,  David Satijn ,  Rik Rademaker ,  Paul Parren ,  Ugur Sahin ,  Friederike Gieseke ,  Alexander Muik ,  Christian Grunwitz

IPC: C07K16/28

Abstract: The present invention relates to novel binding agents and their use in medicine. In particular, the invention relates to binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.

公开(公告)号：US20200079866A1

公开(公告)日：2020-03-12

申请号：US16582534

申请日：2019-09-25

Applicant: BIONTECH SE ,  GENMAB A/S

Inventor： Ugur Sahin ,  Friederike Gieseke ,  Isil Altintas ,  David Satijn ,  Paul Parren

IPC: C07K16/28

Abstract: The present invention relates to binding agents binding to receptors of the TNF superfamily, in particular binding agents binding to at least two different receptors of the TNF superfamily, as well as to their use in medicine. The present invention further relates to nucleic acid molecules encoding such binding agents, to cells comprising such nucleic acid molecules and to pharmaceutical compositions and kits.

公开(公告)号：US20250011797A1

公开(公告)日：2025-01-09

申请号：US18737443

申请日：2024-06-07

Applicant: BioNTech SE ,  TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gG

Inventor： Florian Eberle ,  Ugur Sahin ,  Andreas Kuhn ,  Britta Vallazza ,  Mustafa Diken

IPC: C12N15/68 ,  A61K39/00 ,  A61K48/00 ,  C12N15/67 ,  C12N15/70 ,  C12N15/85 ,  C12P19/34 ,  C12P21/00

Abstract: The present invention relates to nucleic acid molecules containing poly(dA:dT) regions which are stabilized in E.coli, methods of propagating such nucleic acid molecules in E.coli, methods of obtaining RNA, peptides or proteins using such nucleic acid molecules and to RNA which is obtained from such nucleic acid molecules and its use. In particular, the poly(dA:dT) regions contain at least one disruption by a sequence not encoding a sequence solely composed of A residues.

公开(公告)号：US20240355417A1

公开(公告)日：2024-10-24

申请号：US18618412

申请日：2024-03-27

Applicant: BioNTech SE ,  InstaDeep Ltd

Inventor： Alexander Muik ,  Ugur Sahin ,  Asaf Poran ,  Alexandra Walls ,  Yunguan Fu ,  Rafal Okuniewski ,  Nicolas Winfried Pfeuffer

IPC: G16B20/50 ,  G16B40/20 ,  G16B45/00 ,  G16B50/30 ,  G16H50/80

CPC classification number: G16B20/50 ,  G16B40/20 ,  G16B45/00 ,  G16B50/30 ,  G16H50/80

Abstract: The present disclosure, among other things, provides technologies for identifying, characterizing, and/or monitoring variant sequences of a particular reference infections agent. Among other things, systems, methods, and architectures described herein provide visualization and decision support tools that can, e.g., facilitate decision making processes by local authorities and improve pandemic response in terms of, e.g., resource allocation, policy making, and speed tailored vaccine development. The present disclosure also provides tools for analyzing circulating variants to predict mutations likely to increase immune evasion of infectious agents.

公开(公告)号：US20240321387A1

公开(公告)日：2024-09-26

申请号：US18289424

申请日：2022-05-04

Applicant: BioNTech SE ,  InstaDeep Ltd

Inventor： Alexander Muik ,  Asaf Poran ,  Yunpeng Liu ,  Ugur Sahin ,  Karim Beguir ,  Marcin Skwark ,  Thomas Pierrot ,  Yunguan Fu

IPC: G16B15/30 ,  G06N3/045 ,  G06N3/08 ,  G06N5/01 ,  G06N20/00 ,  G16B40/20

CPC classification number: G16B15/30 ,  G06N3/045 ,  G06N3/08 ,  G06N5/01 ,  G06N20/00 ,  G16B40/20

Abstract: A method is provided for identifying a number of variants of concern of a reference disease associated immunogen. The method uses a language model to perform inference on data representing each of a plurality of variants and data representing the reference immunogen. For each of the plurality of variants and the reference immunogen, a characteristic vector is derived from an output feature map of a hidden layer of the language model. For each of the plurality of variants, a measure of distance is generated for the variant that includes calculating a measure of distance between the characteristic vector of the variant and the characteristic vector of the reference immunogen. A semantic change score is calculated for each variant based on the generated measure of distance for that variant. A variant of the reference immunogen is selected based, at least in part, on the generated the semantic change scores.

公开(公告)号：US20240075165A1

公开(公告)日：2024-03-07

申请号：US17988742

申请日：2022-11-16

Applicant: BioNTech SE

Inventor： Ugur Sahin ,  Alptekin Güler ,  Andreas Kuhn ,  Alexander Muik ,  Annette Vogel ,  Kerstin Walzer ,  Sonja Witzel ,  Stephanie Hein ,  Özlem Türeci

IPC: A61K48/00 ,  A61K9/00 ,  A61K9/127 ,  A61K9/51 ,  A61K31/7088 ,  A61K31/7105 ,  A61K31/711 ,  A61K31/7115 ,  A61K31/712 ,  A61K39/00 ,  A61K39/12 ,  A61K39/215 ,  A61P31/14 ,  A61P35/00 ,  B82Y5/00 ,  C12N7/00 ,  C12N15/11 ,  C12N15/67 ,  C12N15/88 ,  C12P19/34

CPC classification number: A61K48/0066 ,  A61K9/0019 ,  A61K9/1271 ,  A61K9/5123 ,  A61K9/5146 ,  A61K31/7088 ,  A61K31/7105 ,  A61K31/711 ,  A61K31/7115 ,  A61K31/712 ,  A61K39/0011 ,  A61K39/12 ,  A61K39/215 ,  A61K48/0033 ,  A61P31/14 ,  A61P35/00 ,  B82Y5/00 ,  C12N7/00 ,  C12N15/11 ,  C12N15/67 ,  C12N15/88 ,  C12P19/34 ,  A61K38/00 ,  A61K2039/53 ,  A61K2039/54 ,  A61K2039/545 ,  C12N2770/18022 ,  C12N2770/18034 ,  C12N2770/18071 ,  C12N2770/20034

Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.